CMPS - Compass Pathways appoints Lori Englebert as Chief Commercial Officer | Benzinga
- New executive appointment made ahead of pivotal study results, potential regulatory approval and subsequent commercialization of investigational COMP360 psilocybin treatment
- Latest of several key executive team hires, rounding out team to take Compass through phase 3 and beyond
LONDON, June 26, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (NASDAQ:CMPS) ("Compass"), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today announced the appointment of Lori Englebert as Chief Commercial Officer, effective July 8, 2024. She will be based in the company's New York City office.
Lori brings multifaceted experience in global pharmaceuticals and joins from Axsome Therapeutics, where she spent nearly five years as a member of the executive team serving as head of commercial and business development and most recently as head of product strategy. She played an integral role in bringing the company from clinical-stage to commercial-stage and was responsible for formulating commercial launch strategy and scaling the commercial organization. Over her career, Lori has launched multiple CNS-focused assets, at Axsome and at Amgen, where she spent nearly a decade in several global brand roles, including neuroscience and oncology/hematology, as well as roles in commercial strategy and operations, corporate strategy and business development.
Lori's appointment follows that of Teri Loxam as Chief Financial Officer in March 2024 and Dr. Michael Gold as Chief Research & Development Officer in May 2024. All three executive team members bring decades of successful strategic leadership and highly relevant experience in drug development.
"With Lori's appointment, and with Teri and Mike joining the company earlier this year, Compass Pathways now has in place an experienced executive team to lead us through our phase 3 program in treatment-resistant depression and prepare for a commercial launch should we receive regulatory approval for COMP360," said Kabir Nath, CEO of Compass Pathways. "Lori's success in scaling commercial organizations across global functions will build on the work we have already begun to inform how to deliver COMP360 to patients and ensure broad and equitable access. I am delighted to welcome Lori to our leadership team, united by our mission to bring better options to people who urgently ...